ISTH 2007

Scientific Programme

Daily Scientific Programme

Sunday, 8 July 2007 - Monday, 9 July 2007 - Tuesday, 10 July 2007 - Wednesday, 11 July 2007

Scientific Sessions

Scientific sessions will take place from Sunday 8 July to Wednesday 11 July 2007.
The Scientific Programme includes (updated on 31 May 2007):

please click on each of the session types below to see the details

Plenary lectures

VKORC1, the molecular target of coumarins	J. Oldenburg (D)
Fibrin and fibrinolysis in infection and host defense	J. Degen (USA)
Von Willebrand disease type 1	I. Peake (UK)
Thrombus formation in vivo	B. Furie (USA)
From megakaryocytes to the platelet	J. Hartwig (USA)
Cell matrix adhesion in vascular development	R. Hynes (USA)

Presidential Symposium

Integrated diagnostic strategy for venous thromboembolism	P.S. Wells (CND)
Distal deep vein thrombosis: worth diagnosing?	S. Schellong (D )/ M. Righini (CH)
Factor Xa or thrombin: which is the better target?	J. Ansell (USA) / J. Weitz (CND)
Thrombosis and bleeding disorders outside the Western countries	P.M. Mannucci (I)

State-of-the-Art lectures

Activated Protein C	J. Griffin (USA)
Exosites in the specificity of blood coagulation reactions	P. Bock (USA)
The central role of thrombin in haemostasis	D. Lane (UK)
SERPINs in haemostasis, thrombosis and fibrinolysis	F. Church (USA)
Structure of fibrin: Impact on clot stability	J. Weisel (USA)
Congenital disorders of fibrinogen	M. Neerman-Arbez (CH)
Regulation of plasminogen activation	R. Medcalf (AUS)
Immune tolerance for Factor VIII inhibitors in hemophilia A: current strategies and future directions	D. Di Michele (USA)
Phenotype heterogeneity of severe haemophilia	M. Van den Berg (NL)
How to estimate bleeding risk in mild bleeding disorders?	F. Rodeghiero (I)
Approach to the diagnosis and management of mild bleeding disorders	M. Greaves (UK)
Investigation and treatment of menorrhagia	P. Kouides (USA)
Vascular proteomics	J. Schnitzer (IL)
Platelet genomics and the risk of atherothrombosis	W. Ouwehand (UK)
Thrombin allostery	E. Di Cera (USA)
From stem cell to megakaryocyte	W. Vainchenker (F)
Models to evaluate antiplatelet agents	P.J. Newman (USA)
Platelets, inflammation and atherosclerosis	M. Gawaz (D)
Programmed autologous cleavage of platelet receptors	M. Berndt (AUS)
Platelet receptor crosstalk in collagen-induced activation of platelets	R. Farndale (UK)
Antiplatelet drug resistance: Molecular mechanisms and laboratory detection	M. Cattaneo (I)
Drug-eluting stents: trading thrombosis for restenosis?	E. van Belle (F)
Cancer and thrombosis: from the molecular mechanisms to the clinical presentations	H.R. Büller (NL)
Combined antiplatelet and anticoagulant therapy: Clinical benefits, risks and costs	J. Eikelboom CND)
Past and future of genetic research in thrombosis	P. Reitsma (NL)
Thrombosis in the elderly: specific issues	F.R. Rosendaal (NL)
Venous and arterial thrombosis: is there a link?	P. Prandoni (I)
Thrombophilia and pregnancy complications: causation or association ?	S. Middeldorp (NL)
Plaque progression and regression in atherothrombosis	J.J. Badimon (USA)
Endothelial Progenitor Cells	J. Pearson (UK)
Zebrafish: from haematology to hydrology	P. Jagadeeswaran (USA)
Endothelial cell heterogeneity and thrombosis	W. Aird (USA)

Symposia

New roles for old coagulation factors
Novel functions of protein S	T. Hackeng (NL)
Role of Factor XII in Thrombosis and Inflammation	T. Renné (DE)
Factor VII activating protease (FSAP)	K. Preissner (DE)

The fibrinolytic system and cell surface proteolysis
Annexin II and fibrinolysis	K. Hajjar (USA)
Cell biology of the u-PA receptor	F. Blasi (IT)
Structure of u-PA / u-PA receptor complex	M. Huang (CND)

Controversies in haemophilia treatment
Gene transfer for inherited bleeding disorders	K. High (USA)
Improved therapeutic agents for haemophilia	P. Lollar (USA)
Plasma-derived versus recombinant products for haemophilia treatment ?	J. Goudemand (FR)

Haemostasis and surgery
Antithrombotic therapy and surgery	C. Samama (FR)
Massive transfusion and coagulopathy: pathophysiology and management	J. Hardy (CND)
Treatment of life threatening bleeding	D. Spahn (CH)

Platelet-pathogen interactions
Platelets and bacteria	D. Cox (IE)
Platelets and viruses	E. Cramer (FR)
Platelets and innate immunity	J. Freedman (CND)

Methodological issues: study design and drug safety
Study design, level of evidence and guidelines	H. Schunemann (IT)
Risk management in the development of new antithrombotic drugs	A. Leizorovicz (FR)
Low-molecular-weight heparin in the elderly with impaired renal function	W. Lim (USA)

Venous tromboembolism risk factors and prophylaxis
Controversial issues regarding thromboprophylaxis in surgical patients	O. Dahl (NO)
Prophylaxis in medical patients: how and for whom?	P. Mismetti (FR)
Obesity, metabolic syndrome and venous tromboembolism	M. Alessi (FR)

Endothelial precursor cells
Hematopoietic stem cells localization in the embryonic vessel wall	E. Dzierzak (NL)
Endothelial progenitors and circulating endothelial cells: regeneration versus degeneration	F. Dignat-George (FR)
Circulating endothelial progenitors in ischemic heart	D. Losordo (USA)

Protein C
Protein C pathway	B. Dahlbäck (SE)
Endothelial Protein C receptor	C. Esmon (USA)
Cellular functions of APC	M. Riewald (USA)

Fibrinolysis and the central nervous system
Regulation of plasminogen activator activation in the central nervous system	D. Lawrence (USA)
The role of t-PA in the nervous system	S. Strickland (USA)
Plasminogen activators and proteases in stroke	G. Del Zoppo (USA)

Haemophilia inhibitors
Anti-idiotypic monoclonal antibodies for treatment of factor VIII inhibitors	J. Saint-Rémy (BE)
Genetic and environmental risk factors for FVIII inhibitor development	J. Astermark (SE)
Rituximab in the treatment of FVIII inhibitors	C. Leissinger (USA)

Rare bleeding disorders
What do we expect from the International Registry?	F. Peyvandi (IT)
Clinical phenotypes and factor VII genotype in congenital factor VII deficiency	J. Schved (FR)
Factor XI phenotype-genotype correlations	A. Zivelin (IL)

New cellular imaging approaches
Visual approach to proteomics	W. Baumeister (DE)
Structural biology of cellular machines	W. Chiu (USA)
New insights into the dynamics of platelet adhesion	S. Jackson (AUS)

Platelet signalling mechanisms
Contact-dependent interactions that affect thrombus growth and stability	L. Brass (USA)
NO/cGMP and ROS regulatory pathways	U. Walter (DE)
Novel platelet membrane receptors and signalling proteins	S. Watson (UK)

Risk stratification and outcome in venous tromboembolism
Long-term outcome after deep vein thrombosis	S. Kahn (CND)
Risk stratification in acute pulmonary embolism: how and what for?	S. Goldhaber (USA)
Long-term prognosis of pulmonary embolism	G. Meyer (FR)

Models of arterial and venous thrombosis
Thrombomodulin - guarding the vascular endothelium	E. Conway (BE)
Platelets and leukocyte interaction with the vessel wall	D. Wagner (USA)
In vivo monitoring of thrombus formation	B. Furie (USA)

Thrombin
Non PAR receptors for Thrombin -	R. De Cristofaro (IT)
Thrombin is a Zymogen-like Enzyme -	J. Huntington (UK)
Protease activated receptors in health and disease -	S. Coughlin (USA)

Current and future assays of haemostasis
Global assay using clot waveform and thrombin generation assays	M. Shima (JP)
Monitoring haemostatic response using dynamic fibrin generation methods	B. Sorensen (DK)
Global assays of platelet function in diagnostic testing	C. Hayward (CND)

The VWF-GPIb axis
The VWF-GPIb axis as a therapeutic target	H. Deckmyn (BE)
The function of GPIb	Z. Ruggeri (USA)
The function of Von Willebrand factor	J. Sadler (USA)

Platelet disorders: clinical aspects
Clinical approach to heparin-induced thrombocytopenia	L. Alberio (CH)
Giant platelet syndromes	C. Balduini (IT)
The spectrum of the platelet response	A. Goodall (UK)

Thrombotic microangiopathies and ADAMTS13
Clinical aspects of hereditary and acquired thrombotic thrombocytopenic purpura	J. Kremer-Hovinga (CH)
ADAMTS13 structure and function	K. Soejima (JP)
Mouse model of hereditary thrombotic thrombocytopenic purpura	D. Motto (USA)

Treatment of venous tromboembolism: controversies
Risk stratification of venous tromboembolism recurrence	M. Rodger (CND)
Optimal duration of anticoagulant treatment in patients with venous tromboembolism	G. Agnelli (IT)
Treatment of anti-phospholipid syndrome	S. Schulman (CND)

Thrombosis in children
Central venous line related thrombosis in children	M. Manco-Johnson (USA)
Paediatric stroke	F. Kirkham (UK)
Management of arterial and venous thrombosis in paediatric patients	A. Chan (CND)

Microparticles
Clinical significance of microparticles	I. Pabinger (AUS)
Role of platelet microparticles in cancer and angiogenesis	D. Varon (IL)
Tissue factor and microparticles	N. Mackman (USA)

more Scientific Programme Information